Clinical trials: DLBCL, open to volunteers
Diffuse Large B Cell Lymphoma
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
The purpose of the study is to assess the safety and efficacy of once daily itacitinib oral administration in participants with diffuse large B-cell lymphoma (DLBCL) who will receive CAR-T cell therapy with axicabtagene…
- Trial name
- NCT05757219
- Testing
- Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Diffuse Large B Cell Lymphoma
Maintenance Hormonal Therapy and DLBCL
the study aims to detect the benefit of maintenance tamoxifen after achieving CR with conventional immuno-chemotherapy and/or radiotherapy in patients with DLDCL
- Trial name
- NCT06355401
- Testing
- Tamoxifen 20mg
- Volunteers
- 100 people
- Sponsor
- Sohag University
Mediastinal Lymphoma, Hodgkin Disease Lymphoma
Proton Therapy for Mediastinal Lymphoma (PROMLY)
The study aims to investigate whether proton therapy is feasible in a national setting and whether proton therapy can reduce the risk of late toxicity (secondary cancers and heart toxicity) compared to foton therapy.
- Conditions
- Mediastinal Lymphoma, Hodgkin Disease Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
- Trial name
- PROMLY (NCT07817641)
- Testing
- Proton therapy
- Where
- Denmark
- Volunteers
- 139 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Pirtobrutinib, Immunochemotherapy
Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement
This is an open-label, prospective, single-arm, multicenter study designed to evaluate the efficacy and safety of MTX plus pirtobrutinib combined with routinely-used clinical chemoimmunotherapy regimens in patients with DLBCL and…
- Conditions
- Pirtobrutinib, Immunochemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, CNS Involvement of Systemic Lymphoma
- Trial name
- NCT07812493
- Testing
- pirtobrutinib+MTX+immunolchemotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Pengpeng Xu
Diffuse Large B-cell Lymphoma
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
This is a double-center, single-arm, phase 2 study to evaluate the efficacy and safety of R-CDOP regimen combined with intrathecal methotrexate in chemo-naive diffuse large B-cell lymphoma patients with high-risk of CNS relapse.
- Trial name
- NCT05257018
- Testing
- R-CDOP+intrathecal MTX
- Where
- 2 sites in China
- Volunteers
- 83 people
- Sponsor
- Fudan University
DLBCL - Diffuse Large B Cell Lymphoma
Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma
This is a single-center, single-arm, prospective study aimed at evaluating the efficacy and safety of orelabrutinib combined with an induction regimen followed by monotherapy maintenance in patients with MCD subtype diffuse large…
- Trial name
- NCT07677813
- Testing
- R-CHOP+Orelabrutinib, POLA-R-CHP+orelabrutinib, R-miniCHOP +orelabrutinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Ou Bai, MD/PHD
DLBCL, Diffuse Large B Cell Lymphoma
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
This is a phase III, randomized, open-label, multicenter trial, conducted in Sweden, Norway, Finland, Denmark, Italy, Australia and New Zealand, in elderly patients with untreated diffuse large B-cell lymphoma.
- Trial name
- POLAR BEAR (NCT04332822)
- Testing
- R-pola-mini-CHP, R-mini-CHOP
- Where
- 69 sites in Australia, Denmark and 5 more
- Volunteers
- 300 people
- Sponsor
- Nordic Lymphoma Group
DLBCL
Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
Patients with CD30 positive DLBCL, primary refractory or in first relapse after R-CHOP or R-CHOP-like therapy will receive brentuximab vedotin in combination with R-DHAP, followed in responsive patients by high dose chemotherapy…
- Trial name
- HOVON 136 NHL (NCT03356054)
- Testing
- R-DHAP, Brentuximab Vedotin
- Where
- Netherlands
- Volunteers
- 37 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
B Cell Malignancies
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
This is a phase I/II trial of T-cell expressing an anti-CD22 Chimeric-Antigen-Receptor (CAR) in patients with CD22 expressing B-cell malignancies.
- Trial name
- NCT07135466
- Testing
- CD22 CAR-T cells
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Diffuse Large B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA)
The goal of this study is to identify biomarkers that will predict outcome to standard and targeted therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- MIMOSA (NCT05746858)
- Testing
- no intervention (observational study)
- Where
- 3 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Relapsed /Refractory DLBCL
Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept
The Double-T trial is a prospective, randomized, single-arm, open-label, multicenter phase II trial investigating a double T-cell therapy strategy, which includes glofitamab with gemcitabine/oxaliplatin (Glofi-Gem/Ox) prior to…
- Trial name
- NCT07542678
- Testing
- Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy, Glofitamab as Consolidation therapy
- Where
- 5 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Long-term Follow up Local Registry Study of Kymriah in South Korea
This study is multicenter, primary data collection, non-interventional registry study to assess long-term safety, secondary malignancy risk, and effectiveness of tisagenlecleucel in patients with B-cell malignancies in a routine…
- Trial name
- NCT06785818
- Testing
- Tisagenlecleucel
- Where
- 18 sites in South Korea
- Volunteers
- 500 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL)
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect…
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL)
- Trial name
- RUBIN (NCT06043011)
- Testing
- Routine care as per site standard.
- Where
- Germany
- Volunteers
- 2,950 people
- Sponsor
- iOMEDICO AG
Diffuse Large B Cell Lymphoma
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
The purpose of this clinical trial is to assess the safety and tolerability of ration therapy followed by receiving epcoritamab or glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma.
- Trial name
- REBEL (NCT07528352)
- Testing
- Epcoritamab, Glofitamab, External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
DLBCL
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
This is a prospective, observational, multicenter, cohort study with 400 newly treated DLBCL patients. To evaluate the clinical efficacy and safety of tucidinostat in the real-world treatment of primary diffuse large B-cell…
- Trial name
- NCT06779435
- Testing
- Low intensity treatment options, Conventional immunochemotherapy regimen
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Ruijin Hospital
Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma
Outpatient Epcoritamab in Large B-cell Lymphoma
The purpose of this study is to measure the efficacy of the study drug, epcoritamab, in participants with relapsed/refractory large B-cell lymphoma.
- Trial name
- NCT06811272
- Testing
- Epcoritamab, Rituximab combined with cyclophosphamide, vincristine, and prednisone, Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Transformed Lymphoma
POLA-R-CHP in the First-line Treatment of Transformed DLBCL
This study aims to evaluate efficacy and safety of POLA-R-CHP in the treatment of patients with transformed DLBCL.
- Trial name
- NCT06743945
- Testing
- POLA-R-CHP
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Lymphoma, Large B-Cell, Diffuse
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells.
- Trial name
- NCT06890884
- Testing
- Zilovertamab vedotin, Rituximab, Cyclophosphamide
- Where
- 148 sites in United States, Belgium and 7 more
- Volunteers
- 594 people
- Sponsor
- Merck Sharp & Dohme LLC
B-cell Non Hodgkin Lymphoma
A Study of ARC-02 in B-cell NHL
This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.
- Trial name
- ABLATE-101 (NCT07691606)
- Testing
- ARC-02, Rituximab
- Where
- 28 sites in United States, Australia and 4 more
- Volunteers
- 140 people
- Sponsor
- Taiho Oncology, Inc.
Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients…
- Conditions
- Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL)
- Trial name
- NCT07424833
- Testing
- APG-3288
- Where
- 6 sites in United States, China
- Volunteers
- 180 people
- Sponsor
- Ascentage Pharma Group Inc.